to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Nine Months Ended September 30, Three Months Ended September 30, 2010 2009 2010 2009 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue:Product Related Revenue, Net
$
5,541,489
$
4,877,551
$
1,922,552
$
1,666,587License Fee Revenue32,00010,175,000-125,000Research and Development Revenue617,6953,918,56164,120297,760Total Revenue6,191,18418,971,1121,986,6722,089,347Cost of Goods Sold:4,738,3924,574,3531,647,4131,598,567Gross Profit1,452,79214,396,759339,259490,780Expenses:General and Administrative3,740,0392,475,6421,105,897631,263Sales and Marketing 738,757723,661266,161268,204Research and Development 920,444863,311271,809238,841Foreign Currency Exchange Losses (Gains), Net137,85251,223(122,691)971Total Expenses5,537,0924,113,8371,521,1761,139,279Income (Loss) from Operations(4,084,300)10,282,922(1,181,917)(648,499)Other Income (Expense) Interest Income46,003113,8989,99242,903Interest Expense(132,657)(160,189)(67,591)(50,323)Gain on Reduction of Accrued Stockholder Litigation410,000---Other(155,260)1,494(155,503)1,494Total Other Income (Expense)168,086(44,797)(213,102)(5,926)Net Income (Loss)
$
(3,916,214)
$
10,238,125
$
(1,395,019)
$
(654,425)Net Income (Loss) per Common ShareBasic
$
(0.13)
$
0.34
$
(0.04)
$
(0.02)Diluted
$
(0.13)
$
0.31
$
(0.04)
$
(0.02)Weighted Average Common Shares Used in Calculating Net Income (Loss) Per Share:Basic30,971,29630,042,58931,063,14730,119,18
'/>"/>
SOURCE Dyadic International, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 20102.
Dyadic International Raises $3 Million in Private Placement of Convertible Notes3.
Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 20104.
Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit5.
Dyadic International Engages The Abraham Group as Strategic Advisor6.
Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference7.
Dyadic International Strengthens Management Team8.
Dyadic International Extends Collaboration With The Scripps Research Institute9.
International Technidyne Corporation Acquired by Warburg Pincus10.
Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team11.
Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs